Daewoong, Boehringer Ingeheim Korea sign strategic partnership agreement

Published: 2010-03-18 06:57:00

Updated: 2010-03-18 06:57:00

Daewoong Pharm and Boehringer Ingeheim Korea (BIK) announced on March 15 that the two companies have signed a strategic partnership agreement to let Daewoong market BIK’s seven leading OTC (over-the-counter) drugs in the domestic market.

These products include Dulcolax, Dulcolax Balance, Buscopan, Mucopect, Mucoangin, Antistax and Pharmaton.

Under the agreement, Daewoong will be responsib...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.